NO20053509L - Anvendelse av adenosin A2a -reseptorantagonister - Google Patents
Anvendelse av adenosin A2a -reseptorantagonisterInfo
- Publication number
- NO20053509L NO20053509L NO20053509A NO20053509A NO20053509L NO 20053509 L NO20053509 L NO 20053509L NO 20053509 A NO20053509 A NO 20053509A NO 20053509 A NO20053509 A NO 20053509A NO 20053509 L NO20053509 L NO 20053509L
- Authority
- NO
- Norway
- Prior art keywords
- adenosine
- receptor antagonists
- plms
- rls
- dystonia
- Prior art date
Links
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 title abstract 2
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 title abstract 2
- 208000027776 Extrapyramidal disease Diseases 0.000 abstract 3
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 3
- 208000014094 Dystonic disease Diseases 0.000 abstract 2
- 208000010118 dystonia Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000737 periodic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43532102P | 2002-12-19 | 2002-12-19 | |
PCT/US2003/040456 WO2005044245A1 (en) | 2002-12-19 | 2003-12-17 | USES OF ADENOSINE A2a RECEPTOR ANTAGONISTS |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20053509D0 NO20053509D0 (no) | 2005-07-18 |
NO20053509L true NO20053509L (no) | 2005-09-16 |
Family
ID=34572685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20053509A NO20053509L (no) | 2002-12-19 | 2005-07-18 | Anvendelse av adenosin A2a -reseptorantagonister |
Country Status (16)
Country | Link |
---|---|
US (2) | US7414058B2 (fi) |
EP (3) | EP2269596A3 (fi) |
JP (3) | JP2006514697A (fi) |
CN (2) | CN100415217C (fi) |
AT (1) | ATE490775T1 (fi) |
AU (2) | AU2003304527B2 (fi) |
BR (1) | BR0317436A (fi) |
DE (1) | DE60335294D1 (fi) |
ES (1) | ES2354875T3 (fi) |
HK (1) | HK1074585A1 (fi) |
MX (1) | MXPA05006790A (fi) |
NO (1) | NO20053509L (fi) |
NZ (1) | NZ540493A (fi) |
TW (1) | TWI331036B (fi) |
WO (1) | WO2005044245A1 (fi) |
ZA (1) | ZA200504478B (fi) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK287748B6 (sk) * | 2000-05-26 | 2011-08-04 | Schering Corporation | Substituované 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidíny, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie |
DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
US20060106040A1 (en) * | 2002-12-19 | 2006-05-18 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
US20060128694A1 (en) * | 2002-12-19 | 2006-06-15 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
JP2006514697A (ja) * | 2002-12-19 | 2006-05-11 | シェーリング コーポレイション | アデノシンA2aレセプターアンタゴニストの使用 |
CN100503609C (zh) * | 2003-04-23 | 2009-06-24 | 先灵公司 | 2-炔基-及2-链烯基-吡唑并-[4,3-e]-1,2,4-三唑并[1,5-c]-嘧啶腺苷A2a受体拮抗剂 |
NZ527142A (en) * | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
WO2005103055A1 (en) * | 2004-04-21 | 2005-11-03 | Schering Corporation | PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS |
US7910613B2 (en) | 2004-09-22 | 2011-03-22 | H. Lundbeck A/S | 2-acylaminothiazole derivatives |
US8455437B2 (en) * | 2005-02-04 | 2013-06-04 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Method to predict and prevent oxygen-induced inflammatory tissue injury |
US7674912B2 (en) * | 2005-04-25 | 2010-03-09 | H. Lundbeck A/S | Pro-drugs of N-thiazol-2-yl-benzamide derivatives |
ATE556712T1 (de) * | 2005-06-07 | 2012-05-15 | Kyowa Hakko Kirin Co Ltd | A2a antagonisten zur behandlung von motorischen störungen |
WO2007035542A1 (en) * | 2005-09-19 | 2007-03-29 | Schering Corporation | 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
AR056080A1 (es) * | 2005-09-23 | 2007-09-19 | Schering Corp | 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine |
ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
WO2009111449A1 (en) | 2008-03-04 | 2009-09-11 | Schering Corporation | 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists |
TWI473614B (zh) * | 2008-05-29 | 2015-02-21 | Kyowa Hakko Kirin Co Ltd | Anti-analgesic inhibitors |
JP5765239B2 (ja) | 2009-03-13 | 2015-08-19 | アドヴィナス・セラピューティックス・リミテッド | 置換縮合ピリミジン化合物 |
EP2499142B1 (en) | 2009-11-09 | 2016-09-21 | Advinus Therapeutics Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
US8435994B2 (en) | 2009-11-16 | 2013-05-07 | Merck Sharp & Dohme Corp. | Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists |
US8473582B2 (en) * | 2009-12-16 | 2013-06-25 | International Business Machines Corporation | Disconnected file operations in a scalable multi-node file system cache for a remote cluster file system |
WO2011101861A1 (en) | 2010-01-29 | 2011-08-25 | Msn Laboratories Limited | Process for preparation of dpp-iv inhibitors |
ES2579949T3 (es) | 2010-02-05 | 2016-08-17 | Heptares Therapeutics Limited | Derivados de 1,2,4-triazin-4-amina |
CN103261202B (zh) * | 2010-09-24 | 2016-01-20 | 阿迪维纳斯疗法有限公司 | 作为腺苷受体拮抗剂的稠合三环化合物 |
WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
WO2012135084A1 (en) * | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
WO2014101113A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
CN105025899B (zh) * | 2012-12-28 | 2017-08-18 | 默沙东公司 | 具有A2A拮抗剂性质的杂二环取代的‑[1,2,4]三唑并[1,5‑c]喹唑啉‑5‑胺化合物 |
WO2014101120A1 (en) * | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
WO2018013951A1 (en) * | 2016-07-15 | 2018-01-18 | Northwestern University | Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias |
CN110809577A (zh) * | 2017-06-30 | 2020-02-18 | 雷沃医疗有限公司 | 腺苷a2a受体的调节剂 |
US20200316077A1 (en) | 2017-12-19 | 2020-10-08 | Impetis Biosciences Ltd. | Pharmaceutical composition for the treatment of cancer |
AU2019205661B2 (en) | 2018-01-04 | 2022-06-30 | Impetis Biosciences Ltd. | Tricyclic compounds, compositions and medicinal applications thereof |
DE102019116986A1 (de) | 2019-06-24 | 2020-12-24 | Helmholtz-Zentrum Dresden-Rossendorf E. V. | Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate |
JP2022540583A (ja) * | 2019-07-17 | 2022-09-16 | テオン セラピューティクス,インク. | アデノシンa2a受容体アンタゴニスト及びその使用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
ATE208199T1 (de) * | 1993-07-27 | 2001-11-15 | Kyowa Hakko Kogyo Kk | Arzneimittel gegen parkinsonsche krankheit |
IT1277392B1 (it) * | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
US5933964A (en) * | 1996-07-17 | 1999-08-10 | Wahl Clipper Corporation | Cutter blade for hair clippers |
AU1251499A (en) | 1997-11-26 | 1999-06-15 | Cerebrus Limited | (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders |
GB9819384D0 (en) * | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
GB9915437D0 (en) * | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
SK287748B6 (sk) * | 2000-05-26 | 2011-08-04 | Schering Corporation | Substituované 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidíny, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie |
GB0100624D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
MXPA03009185A (es) * | 2001-04-09 | 2004-02-17 | Neurosearch As | Antagonistas de receptor a2a de adenosina combinados con compuestos de actividad neurotrofica en el tratamiento de la enfermedad de parkinson. |
EP1425017A1 (en) * | 2001-09-13 | 2004-06-09 | Schering Corporation | Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic |
PE20030477A1 (es) | 2001-10-15 | 2003-06-06 | Schering Corp | ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a |
US6875772B2 (en) * | 2001-11-30 | 2005-04-05 | Schering Corporation | [1,2,4]-Triazole bicyclic adeonsine A2a receptor antagonists |
AR038366A1 (es) | 2001-11-30 | 2005-01-12 | Schering Corp | Compuestos de 1,2,4-triazolo [1,5-c] pirimidinas sustituidas, antagonistas del receptor de adenosina a2a, composiciones farmaceuticas, el uso de dichos compuestos para la manufactura de un medicamento para el tratamiento de enfermedades del sistema nervioso central y un kit que comprende combinacion |
WO2003048165A1 (en) | 2001-11-30 | 2003-06-12 | Schering Corporation | ADENOSINE A2a RECEPTOR ANTAGONISTS |
ES2716404T3 (es) | 2002-01-28 | 2019-06-12 | Kyowa Hakko Kogyo Kk | Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento |
MXPA05001461A (es) * | 2002-08-30 | 2005-06-03 | Kyowa Hakko Kogyo Kk | Antagonistas del receptor a2a de adenosina para el tratamiento del sindrome de las piernas inquietas o trastornos relacionados. |
JP2006514697A (ja) * | 2002-12-19 | 2006-05-11 | シェーリング コーポレイション | アデノシンA2aレセプターアンタゴニストの使用 |
CN100503609C (zh) * | 2003-04-23 | 2009-06-24 | 先灵公司 | 2-炔基-及2-链烯基-吡唑并-[4,3-e]-1,2,4-三唑并[1,5-c]-嘧啶腺苷A2a受体拮抗剂 |
-
2003
- 2003-12-17 JP JP2005510511A patent/JP2006514697A/ja not_active Withdrawn
- 2003-12-17 EP EP10186087A patent/EP2269596A3/en not_active Withdrawn
- 2003-12-17 US US10/738,906 patent/US7414058B2/en not_active Expired - Fee Related
- 2003-12-17 BR BR0317436-0A patent/BR0317436A/pt not_active IP Right Cessation
- 2003-12-17 TW TW092135740A patent/TWI331036B/zh not_active IP Right Cessation
- 2003-12-17 WO PCT/US2003/040456 patent/WO2005044245A1/en active Application Filing
- 2003-12-17 CN CNB2003801070872A patent/CN100415217C/zh not_active Expired - Fee Related
- 2003-12-17 NZ NZ540493A patent/NZ540493A/en not_active IP Right Cessation
- 2003-12-17 DE DE60335294T patent/DE60335294D1/de not_active Expired - Lifetime
- 2003-12-17 MX MXPA05006790A patent/MXPA05006790A/es active IP Right Grant
- 2003-12-17 AT AT03818838T patent/ATE490775T1/de not_active IP Right Cessation
- 2003-12-17 ES ES03818838T patent/ES2354875T3/es not_active Expired - Lifetime
- 2003-12-17 AU AU2003304527A patent/AU2003304527B2/en not_active Ceased
- 2003-12-17 EP EP10186097A patent/EP2295047A3/en not_active Withdrawn
- 2003-12-17 EP EP03818838A patent/EP1578409B1/en not_active Expired - Lifetime
- 2003-12-17 CN CNA2008101361548A patent/CN101310724A/zh active Pending
-
2005
- 2005-05-31 ZA ZA200504478A patent/ZA200504478B/en unknown
- 2005-07-18 NO NO20053509A patent/NO20053509L/no not_active Application Discontinuation
- 2005-09-28 HK HK05108564.4A patent/HK1074585A1/xx not_active IP Right Cessation
-
2008
- 2008-07-29 US US12/181,736 patent/US20090029967A1/en not_active Abandoned
-
2010
- 2010-08-06 JP JP2010177518A patent/JP2011006431A/ja active Pending
- 2010-08-31 AU AU2010214749A patent/AU2010214749B2/en not_active Ceased
-
2013
- 2013-01-29 JP JP2013013961A patent/JP2013136592A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US20040138235A1 (en) | 2004-07-15 |
CN100415217C (zh) | 2008-09-03 |
AU2003304527B2 (en) | 2010-09-09 |
TW200505927A (en) | 2005-02-16 |
US20090029967A1 (en) | 2009-01-29 |
CN1728990A (zh) | 2006-02-01 |
EP1578409A1 (en) | 2005-09-28 |
CN101310724A (zh) | 2008-11-26 |
JP2011006431A (ja) | 2011-01-13 |
NO20053509D0 (no) | 2005-07-18 |
JP2013136592A (ja) | 2013-07-11 |
EP1578409B1 (en) | 2010-12-08 |
ATE490775T1 (de) | 2010-12-15 |
JP2006514697A (ja) | 2006-05-11 |
EP2295047A3 (en) | 2011-05-18 |
ZA200504478B (en) | 2006-02-22 |
EP2269596A3 (en) | 2011-09-14 |
US7414058B2 (en) | 2008-08-19 |
NZ540493A (en) | 2008-04-30 |
EP2295047A2 (en) | 2011-03-16 |
AU2003304527A1 (en) | 2005-05-26 |
MXPA05006790A (es) | 2005-09-08 |
BR0317436A (pt) | 2005-11-16 |
AU2010214749A1 (en) | 2010-09-23 |
WO2005044245A1 (en) | 2005-05-19 |
EP2269596A2 (en) | 2011-01-05 |
DE60335294D1 (de) | 2011-01-20 |
HK1074585A1 (en) | 2005-11-18 |
TWI331036B (en) | 2010-10-01 |
AU2010214749B2 (en) | 2011-06-09 |
ES2354875T3 (es) | 2011-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20053509L (no) | Anvendelse av adenosin A2a -reseptorantagonister | |
NO20082175L (no) | Adenosin A2A-reseptorantagonister for behandling av ekstrapyramidalt syndrom og andre bevegelsesforstyrrelser | |
DK1543011T3 (da) | Thienopyrrolyl- og furanopyrrolylforbindelser og deres anvendelse som histamin H4-receptorligander | |
CL2008001920A1 (es) | Composicion farmaceutica que comprende un inhibidor de la pde 2, un agonista del receptor selectivo e2 y un portador; y uso en el tratamiento de fractura y/o defecto oseo (div. sol. 3179-04). | |
CL2007001380A1 (es) | Compuestos derivados de tiazolo-pirimidina-urea, antiparasitos activos del receptor de adenosina a2b; composicion farmaceutica que comprende a dichos compuestos; y su uso del compuesto en el tratamiento y profilaxis de diabetes, retinopatia asma y diarrea. | |
HRP20050318A2 (en) | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflamatory, ischaemic and remodelling processes | |
NO20074943L (no) | Roflumilast for behandlingen av diabetes mellitus | |
NO20082414L (no) | Inhibitorer av AKT-aktivitet | |
NO20064929L (no) | Sulfonamid-tiazolpyrldinderivater som glukokinaseaktivatorer anvendelige i behandlingen av type 2 diabetes | |
NO20083358L (no) | Piperasinyl derivater som modulatorer for kjemokine reseptor aktivitet | |
NO20062417L (no) | N-tiazol-2-yl-benzamidderivater | |
NO20064976L (no) | Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser | |
NO20053144L (no) | Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler. | |
NO20020792L (no) | Behandling av rastlöse ben syndrom med en kombinasjon av clonidin og opioid | |
NO20080052L (no) | G-Protein kopplede reseptoragonister | |
TNSN06053A1 (en) | 6-substituted anilino purines as rtk inhibitors | |
NO20072665L (no) | Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser | |
NO20055211L (no) | Anti-fungale forbindelser og fremgangsmater for anvendelse | |
DE602005023884D1 (de) | Wässrige grundierungszusammensetzung, oberflächenbehandlungsverfahren unter verwendung derselben und mehrschichtige struktur | |
CY1108457T1 (el) | Παραγωγα ξανθινης ως ανταγωνισται υποδοχεως α2β αδενοσινης | |
BRPI0514579A (pt) | composto, composição farmacêutica, uso de um composto, combinação de um composto e gaboxadol, e, processo para preparo de um composto | |
NO20060702L (no) | Aminokinolinderivater og deres anvendelse som adenosin A3 ligander | |
NO20061981L (no) | Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist | |
DE60231386D1 (de) | Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson | |
NO20076391L (no) | Sammensetninger og metoder for behandling av tilstander relatert til efrinsignaler med cupredoxin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MERCK SHARP AND DOHME CORP, US Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |